Optimizing miltefosine treatment for leishmaniasis patients
Treatments studied
Part of Infections, Skin clinical trials.
This trial tests how well miltefosine works for people with leishmaniasis, a skin infection from a parasite. It aims to find the best way to use this medicine to help patients get better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have leishmaniasis (confirmed by a lab test or skin sample).
- You must be older than 2 years old.
- Your doctor has decided to start treatment with miltefosine (a pill or liquid medicine).
- If you are a woman who can have children, you must agree to use birth control (like an IUD, implant, or shot) for 6 months.
- You must be willing to stay in the hospital for the whole treatment period.
- You must have normal blood test results (check with your doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares different drugs to find the best one for treating cutaneous leishmaniasis, a skin infection that causes sores. You might get one of several treatments, and the goal is to see which works best and is safest for patients like you.
This study tests how your immune system responds to parts of a potential vaccine for leishmaniasis. Doctors will take small blood or skin samples to see if your body's cells react to these vaccine pieces, which could help design a better vaccine in the future.
This trial tests a combination of two medicines—inhaled pentamidine and oral miltefosine—to treat mucosal leishmaniasis, a parasitic infection of the nose, mouth, and throat. It may be an option for people in Bolivia who have not been treated recently.
This study tests a gel containing miltefosine (a medicine) applied directly to the skin sores caused by cutaneous leishmaniasis. The goal is to see if the gel is safe and works to clear the sores.
This study tests two new oral medicines (called LXE408) against an existing oral treatment (miltefosine) for people with a first episode of localized cutaneous leishmaniasis (skin sores caused by a parasite). The goal is to see if the new medicines are safe and work better at healing the sores.
This trial tests whether adding a special laser treatment (fractional CO₂ laser) to the standard injected medicine (Glucantime) helps heal skin sores from a parasite infection better than the medicine alone. It may offer a more effective way to clear the sores and improve healing.
Hear when a new Cutaneous Leishmaniases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.